Developer docs
API playgroundTry for free, no card

Search company profiles

SOTHEMA

Full company profile

uuid003abc4

Namestring
SOTHEMA
Legal namestring
Sothema
Websiteurl
sothema.com
Company typeenum
Private
Founded yearint
1976
Descriptiontext

SOTHEMA is a Moroccan pharmaceutical manufacturer founded in 1976 and headquartered in Bouskoura, Morocco. The company develops, manufactures, and distributes pharmaceutical products and describes itself as Morocco's leading pharmaceutical company, operating with a workforce of between 1,001 and 5,000 employees. Its commercial footprint extends across Morocco, sub-Saharan Africa, and the Middle East through its own proprietary distribution network, and the company is publicly listed (cas:SOT). Core business activity is industrial production of medicines, with stated therapeutic focus areas including mental health and women's well-being. The company's distribution network, regulatory licensing, and long-established manufacturing base constitute its primary commercial assets and the basis of its regional market position.

Sothema's revenue model is anchored in one-time sales of manufactured pharmaceutical products distributed through its own channels across its three operating regions. The company supplements its own portfolio by serving as an industrial and distribution platform for partner brands. In February 2026, Sothema signed a memorandum of understanding with Naali at the Officine Expo in Marrakech to market and distribute saffron-based dietary supplements targeting mental health and women's well-being segments. This is consistent with a stated therapeutic diversification strategy that extends the company beyond traditional prescription pharmaceuticals into consumer health adjacencies. In July 2025, Sothema acquired Soludia Maghreb, signaling an active inorganic growth posture. Go-to-market is primarily enterprise field sales through its own distribution network, with selective partnership development at industry events.

No specific pricing models, contract structures, or customer logos are publicly disclosed, and the company does not present an AI, software, or digital health product surface. The business is a conventional branded-generic pharmaceutical manufacturer whose competitive positioning rests on industrial scale, regulatory licensing, distribution reach, and brand longevity rather than technology differentiation.

Short descriptiontext

SOTHEMA is Morocco's leading pharmaceutical manufacturer, founded in 1976, producing and distributing medicines across Morocco, sub-Saharan Africa, and the Middle East through its own industrial and distribution platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersBouskoura, Morocco
HQ citystring
Bouskoura
HQ countrystring
Morocco
HQ regionstring
Africa
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, generic medicines, pharmaceutical distribution, therapeutic products, dietary supplements
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Manufacturing
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Manufacturing and Distribution
TypeOne Time License
Description

Sothema operates as a leading pharmaceutical company in Morocco, manufacturing and distributing pharmaceutical products across Morocco, sub-Saharan Africa, and the Middle East. The company generates revenue through the production and sale of pharmaceutical products and is expanding into dietary supplements through strategic partnerships.

en.yabiladi.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SOTHEMA manufactures and distributes pharmaceutical products for therapeutic use across Morocco, sub-Saharan Africa, and the Middle East. The company operates industrial-scale drug manufacturing facilities and an extensive proprietary distribution network, and is expanding into saffron-based dietary supplements through a strategic partnership with Naali to address mental health and women's well-being segments.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

SOTHEMA is Morocco's leading pharmaceutical company founded in 1976, operating as a manufacturer and distributor of pharmaceutical products. The company leverages industrial capabilities and an extensive distribution network spanning Morocco, sub-Saharan Africa, and the Middle East. Through a strategic partnership with Naali (established in 2020), Sothema has expanded into dietary supplements, specifically saffron-based products targeting mental health and women's well-being. The partnership supports Sothema's therapeutic diversification strategy.

Product and service2 records
1Sothema Pharmaceutical Products
CategoryPharmaceuticals
Description

Morocco's leading portfolio of manufactured pharmaceutical products covering multiple therapeutic areas, distributed across Morocco, sub-Saharan Africa, and the Middle East through SOTHEMA's proprietary distribution network. Targeted at pharmaceutical wholesalers, pharmacy chains, hospitals, and institutional healthcare providers.

2Naali Saffron-Based Dietary Supplements
CategoryDietary supplements
Description

Saffron-based dietary supplements focused on mental health and women's well-being, manufactured by Naali and distributed through SOTHEMA's pharmaceutical-grade industrial capabilities and regional distribution network following the 2026 partnership. Targeted at health-conscious consumers and wellness retail channels in Morocco and international markets.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Sothema signed a memorandum of understanding with Naali at the 2026 Officine Expo in Marrakech to market Naali's saffron-based dietary supplements across Morocco and internationally. The partnership leverages Sothema's industrial capabilities and distribution network spanning Morocco, sub-Saharan Africa, and the Middle East to expand Naali's products focused on mental health and women's well-being. This agreement supports Sothema's therapeutic diversification strategy while providing Naali with structured growth avenues and broader market access.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SOTHEMA

Pharmaceutical Manufacturingsothema.com

SOTHEMA is Morocco's leading pharmaceutical manufacturer, founded in 1976, producing and distributing medicines across Morocco, sub-Saharan Africa, and the Middle East through its own industrial and distribution platform.

What SOTHEMA does

SOTHEMA is a Moroccan pharmaceutical manufacturer founded in 1976 and headquartered in Bouskoura, Morocco. The company develops, manufactures, and distributes pharmaceutical products and describes itself as Morocco's leading pharmaceutical company, operating with a workforce of between 1,001 and 5,000 employees. Its commercial footprint extends across Morocco, sub-Saharan Africa, and the Middle East through its own proprietary distribution network, and the company is publicly listed (cas:SOT). Core business activity is industrial production of medicines, with stated therapeutic focus areas including mental health and women's well-being. The company's distribution network, regulatory licensing, and long-established manufacturing base constitute its primary commercial assets and the basis of its regional market position.

Sothema's revenue model is anchored in one-time sales of manufactured pharmaceutical products distributed through its own channels across its three operating regions. The company supplements its own portfolio by serving as an industrial and distribution platform for partner brands. In February 2026, Sothema signed a memorandum of understanding with Naali at the Officine Expo in Marrakech to market and distribute saffron-based dietary supplements targeting mental health and women's well-being segments. This is consistent with a stated therapeutic diversification strategy that extends the company beyond traditional prescription pharmaceuticals into consumer health adjacencies. In July 2025, Sothema acquired Soludia Maghreb, signaling an active inorganic growth posture. Go-to-market is primarily enterprise field sales through its own distribution network, with selective partnership development at industry events.

No specific pricing models, contract structures, or customer logos are publicly disclosed, and the company does not present an AI, software, or digital health product surface. The business is a conventional branded-generic pharmaceutical manufacturer whose competitive positioning rests on industrial scale, regulatory licensing, distribution reach, and brand longevity rather than technology differentiation.

SOTHEMA firmographics

Firmographics
Name
SOTHEMA
Legal name
Sothema
Website
https://sothema.com
Company type
Private
Founded year
1976
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
SOTHEMA is Morocco's leading pharmaceutical manufacturer, founded in 1976, producing and distributing medicines across Morocco, sub-Saharan Africa, and the Middle East through its own industrial and distribution platform.
Ownership category
akta.pro rank

Where SOTHEMA is headquartered

Location

Headquarters

HQ city
Bouskoura
HQ country
Morocco
HQ region
Africa

Offices1 record

Markets served

SOTHEMA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Manufacturing and Distribution: Sothema operates as a leading pharmaceutical company in Morocco, manufacturing and distributing pharmaceutical products across Morocco, sub-Saharan Africa, and the Middle East. The company generates revenue through the production and sale of pharmaceutical products and is expanding into dietary supplements through strategic partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

SOTHEMA product offering

Product offering

Core offering

SOTHEMA manufactures and distributes pharmaceutical products for therapeutic use across Morocco, sub-Saharan Africa, and the Middle East. The company operates industrial-scale drug manufacturing facilities and an extensive proprietary distribution network, and is expanding into saffron-based dietary supplements through a strategic partnership with Naali to address mental health and women's well-being segments.

Product overview

SOTHEMA is Morocco's leading pharmaceutical company founded in 1976, operating as a manufacturer and distributor of pharmaceutical products. The company leverages industrial capabilities and an extensive distribution network spanning Morocco, sub-Saharan Africa, and the Middle East. Through a strategic partnership with Naali (established in 2020), Sothema has expanded into dietary supplements, specifically saffron-based products targeting mental health and women's well-being. The partnership supports Sothema's therapeutic diversification strategy.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sothema Pharmaceutical Products Morocco's leading portfolio of manufactured pharmaceutical products covering multiple therapeutic areas, distributed across Morocco, sub-Saharan Africa, and the Middle East through SOTHEMA's proprietary distribution network. Targeted at pharmaceutical wholesalers, pharmacy chains, hospitals, and institutional healthcare providers.
  • Naali Saffron-Based Dietary Supplements Saffron-based dietary supplements focused on mental health and women's well-being, manufactured by Naali and distributed through SOTHEMA's pharmaceutical-grade industrial capabilities and regional distribution network following the 2026 partnership. Targeted at health-conscious consumers and wellness retail channels in Morocco and international markets.

Companies that use SOTHEMA

Customer profile

Segments1 record

Ideal customer profiles2 records

SOTHEMA technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

SOTHEMA partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • NaalicoreStrategic or Co-development Partner · 1 January 2026Sothema signed a memorandum of understanding with Naali at the 2026 Officine Expo in Marrakech to market Naali's saffron-based dietary supplements across Morocco and internationally. The partnership leverages Sothema's industrial capabilities and distribution network spanning Morocco, sub-Saharan Africa, and the Middle East to expand Naali's products focused on mental health and women's well-being. This agreement supports Sothema's therapeutic diversification strategy while providing Naali with structured growth avenues and broader market access.

Scale indicators2 records

Recent moves4 records

Expansion highlights5 records

SOTHEMA competitors and assessment

Company assessment

Market position

Weaknesses5 records

Competitive moat4 records

Customer concentration

SOTHEMA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SOTHEMA leadership team

Management profile

Number of profiles

SOTHEMA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SOTHEMA M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SOTHEMA

What does SOTHEMA do?

SOTHEMA manufactures and distributes pharmaceutical products for therapeutic use across Morocco, sub-Saharan Africa, and the Middle East. The company operates industrial-scale drug manufacturing facilities and an extensive proprietary distribution network, and is expanding into saffron-based dietary supplements through a strategic partnership with Naali to address mental health and women's well-being segments.

Is SOTHEMA a public or private company?

SOTHEMA is a private company. It is classified as public and is currently operating.

When was SOTHEMA founded?

SOTHEMA was founded in 1976. It employs 1,001 to 5,000 people.

Where is SOTHEMA based?

SOTHEMA is headquartered in Bouskoura, Morocco, in the Africa region.

How does SOTHEMA make money?

One revenue line is on record: pharmaceutical Manufacturing and Distribution.

Does SOTHEMA have an API?

No public API is recorded for SOTHEMA.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
https://www.moroccoworldnews.com/Sothema Signs Agreement to Acquire 100% of Ramo PharmSothema signed an agreement to acquire 100% of Ramo Pharm, a Casablanca-based dietary supplement company. The deal is subject to Competition Council authorization and aims to strengthen Sothema's wellness portfolio and support international expansion. Sothema reported MAD 1.8 billion revenue in H1 2026, up 16% year-over-year.https://www.moroccoworldnews.com/Forbes: Two Moroccans Among MENA’s Top Healthcare Leaders in 2026Lamia Tazi and Ayman Cheikh-Lahlou, CEOs of Sothema and Cooper Pharma, ranked 22nd and 31st in Forbes Middle East's 2026 healthcare leaders list. Sothema operates 10 facilities with 350 products, while Cooper Pharma has nine plants and exports 12% of production.YabiladiSothema and Naali partner to boost saffron-based dietary supplements in MoroccoAt the 2026 Officine Expo in Marrakech, Sothema, Morocco's leading pharmaceutical company founded in 1976, signed a memorandum of understanding with Naali, a saffron-based dietary supplement brand established in 2020, to market Naali's products across Morocco and internationally. The partnership will leverage Sothema's industrial capabilities and distribution network spanning Morocco, sub-Saharan Africa, and the Middle East to expand Naali's saffron-based supplements focused on mental health and women's well-being. The agreement supports Sothema's therapeutic diversification strategy while providing Naali with structured growth avenues and broader market access.Forbes MELamia TaziIn July 2025, SOTHEMA agreed to acquire 99.99% of the share capital of Soludia Maghreb for nearly $111 million. The company, which operates eight production units, reported revenue of $306 million in 2024 and launched 18 products that year. Lamia Tazi, the CEO, has been with SOTHEMA since 1997 and has overseen significant operational growth.Billionaires.AfricaMoroccan pharma executive Lamia Tazi gains $8.14 million from Sothema stakeSothema's stock has surged 14.6% in 2025, increasing the market value of Lamia Tazi's 8.19% stake by $8.01 million, reversing losses from the previous year. The pharmaceutical company's market capitalization now exceeds $760 million, reflecting strong returns for investors and renewed confidence in its growth potential. Under Tazi's leadership, Sothema continues to strengthen its position in North Africa's pharmaceutical industry, producing about 60 million units annually and partnering with multinational laboratories.Forbes MELamia TaziLamia Tazi, Chairwoman and CEO of Sothema, was included in Forbes' list of the Middle East’s 100 Most Powerful Businesswomen for 2025. During the first nine months of 2024, Sothema reported $203.7 million in revenues and expanded its operations with a new $20 million storage facility opened in November.Forbes MELamia TaziSothema launched more than 20 new products and signed an innovation agreement with the King Mohamed VI Foundation for Sciences and Health in 2023, generating $254 million in revenue. Lamia Tazi, the company's Chairwoman & CEO, was recognized on Forbes' list of The Middle East’s Top 100 Healthcare Leaders 2024. This recognition highlights Sothema's ongoing contributions to the pharmaceutical sector under Tazi's leadership since she assumed her current role in 2019.Billionaires.AfricaMoroccan pharma leader Lamia Tazi's stake in Sothema drops $4.5 millionLamia Tazi's stake in the Moroccan pharmaceutical company Sothema has decreased by MAD44.22 million ($4.5 million) over the past 27 days due to a decline in Sothema's share price. The company's market capitalization has fallen below $700 million, and its year-to-date performance is now negative with a 4.5% loss. Sothema, which annually manufactures around 60 million pharmaceutical units, has seen its shares drop over 7%, impacting investors and highlighting market volatility.Forbes MELamia TaziForbes included Lamia Tazi, Chairwoman and CEO of Sothema, in its list of The Middle East’s 100 Most Powerful Businesswomen for 2024. Under her leadership since 2019, Sothema has expanded its operations, including opening a scientific representative office in Saudi Arabia in October 2023.Business Wire BlogRegen Lab partners with Morocco's Ministries of Health and Industry, Dassault Systèmes, Baylor College of Medicine (US) and SOTHEMA to accelerate regenerative medicine in Morocco and AfricaRegen Lab signed a collaboration agreement with Morocco's Ministries of Health and Industry, Dassault Systèmes, Baylor College of Medicine, and SOTHEMA to accelerate regenerative medicine in Morocco and Africa. The partnership will develop regulatory standards, conduct clinical research, and launch the InSiDDe platform for accessible medicines. It also aims to train medical staff and build a clinical research hospital.